We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Cardiac Patients Given Less Blood During Transfusions Do Well

By LabMedica International staff writers
Posted on 24 Dec 2014
Blood transfusion might affect long-term mortality by changing immune function and thus potentially increasing the risk of subsequent infections and cancer recurrence.

Compared with a restrictive transfusion strategy, a more liberal strategy could reduce cardiac complications by lowering myocardial damage, thereby reducing future deaths from cardiovascular disease. More...


Clinicians at the Robert Wood Johnson Medical School (New Brunswick, NJ, USA) working with colleagues from several other institutions, recruited 2,016 patients from 47 hospitals across the USA and Canada. Patients aged 50 years and older with a hemoglobin concentration lower than 100 g/L within three days after undergoing surgery to repair a hip fracture, and a history of cardiovascular disease or risk factors for cardiovascular disease were enrolled in the randomized controlled trial. Half of the patients received larger quantities of transfused blood; and the other half received transfusions that were smaller by as much as two thirds.

The total population of 2,016 enrolled patients had a mean age of 81.6 years (range 5 to 103 years), 1,527 (76%) were women, and 1,268 (63%) had cardiovascular disease. The mean pre-transfusion hemoglobin concentration was 92 ± 5 g/L in the liberal transfusion strategy group and 79 ± 6 g/L in the restrictive transfusion strategy group. The number of units of red blood cells transfused post-randomization in the liberal transfusion strategy was 2.9-times larger than that in the restrictive transfusion strategy. Long-term mortality did not differ significantly between the two treatment groups as 432 (43.2%) of 999 patients died in the liberal transfusion strategy group and 409 (40.8%) of 1,003 died in the restrictive strategy group. The cause of death did not differ between the transfusion strategies and the proportion of deaths from cardiovascular disease, cancer, and infections were nearly identical in the two groups of the trial.

Jeffrey L. Carson, MD, a professor and lead author of the study said, “Physicians performing surgeries and other procedures judge whether blood is needed based on how much they have seen the patient lose and by closely watching vital signs such as blood pressure. If physicians overestimate and provide too much blood, the patient's circulatory system can be overloaded and breathing can be affected. The risk of infection can also increase. There are definite risks associated with transfusion. The classic ones are hepatitis and human immunodeficiency virus (HIV). They are as rare as being hit by lightning, but even so, why give more blood to anyone if you can't show it benefits them?” The study was published on December 9, 2014, in the journal the Lancet.

Related Links:

Robert Wood Johnson Medical School 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: WashU Medicine researchers found that dozens of blood proteins shift during Alzheimer’s treatment and may help monitor the effects of the medication. (Image Credit: Matt Miller/WashU Medicine)

Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment

Patients with early-stage Alzheimer’s disease may receive anti-amyloid therapy to clear amyloid protein deposits from the brain. These treatments can slow disease progression, but they do not cure the... Read more

Molecular Diagnostics

view channel
Image: University of Florida scientists Hugh Fan, Ph.D., and John Lednicky, Ph.D., led the development of a cost-effective, accurate handheld device capable of simultaneously testing for seven different mosquito-borne viruses. (Image Credit: UF Health photo by Hannah Clark)

Portable Test Differentiates Seven Mosquito-Borne Viruses at Point of Care

Mosquito-borne viral illnesses can present with overlapping symptoms such as fever, joint pain, fatigue, and rash, making them difficult to distinguish without laboratory testing. In these settings, clinicians... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: Each PhAST instrument supports random-access processing of up to four samples simultaneously, delivering a throughput of up to 12 samples per eight-hour shift. (Photo courtesy of PhAST)

FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures

Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.